Exercise of Share Options and Total Voting Rights

Ergomed

22/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221122:nRSV1281Ha&default-theme=true

RNS Number : 1281H  Ergomed plc  22 November 2022

 PRESS RELEASE

 

 

Exercise of Share Options and Total Voting Rights

 

 

Guildford, UK - 22 November 2022: Ergomed plc (LSE: ERGO) ("Ergomed" or the
"Company") announces that, following an exercise of share options, application
has been made to AIM for the admission of 40,000 new ordinary shares of 1p
each in the capital of the Company (the "New Ordinary Shares").

 

Admission to trading on AIM of the New Ordinary Shares ("Admission") is
expected to occur on 24 November 2022.  Following Admission, the New Ordinary
Shares will rank pari passu in all respects with the Company's existing
ordinary shares.

 

Following Admission, the total number of ordinary shares with voting rights in
issue will be 50,169,305. This figure may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure Guidance and
Transparency Rules.

 

 

 

ENDS

 

Enquiries:

 

Ergomed plc
 
Tel: +44 (0) 1483 402 975

Dr Miroslav Reljanović (Executive Chairman)

Richard Barfield (Chief Financial Officer)

Keith Byrne (Senior Vice-President, Capital Markets & Strategy)

 

Numis
 
Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Euan Brown (Nominated Adviser)

James Black (Broker)

 

Peel Hunt
LLP
Tel: +44 (0) 20 7418 8900

James Steel / Dr Christopher Golden

 

Consilium Strategic
Communications                                 Tel:
+44 (0) 20 3709 5700

Chris Gardner / Matthew Neal
 
ergomed@consilium-comms.com

Angela Gray

 

 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing services business includes an
industry-leading suite of specialist pharmacovigilance (PV) solutions,
integrated under the PrimeVigilance brand, a full range of high-quality
clinical research and trial management services under the Ergomed brand (CRO)
and mission-critical regulatory compliance and consulting services under the
ADAMAS brand. For further information, visit: http://ergomedplc.com
(http://ergomedplc.com/) .

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBBBPTMTITBRT